-
Je něco špatně v tomto záznamu ?
SLN biopsy in cervical cancer patients with tumors larger than 2cm and 4cm
L. Dostálek, M. Zikan, D. Fischerova, R. Kocian, A. Germanova, F. Frühauf, L. Dusek, J. Slama, P. Dundr, K. Nemejcova, D. Cibula,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
NV16-31643A
MZ0
CEP - Centrální evidence projektů
- MeSH
- adenokarcinom diagnóza patologie MeSH
- adenoskvamózní karcinom diagnóza patologie MeSH
- biopsie sentinelové lymfatické uzliny MeSH
- dospělí MeSH
- falešně negativní reakce MeSH
- lidé středního věku MeSH
- lidé MeSH
- lymfadenektomie MeSH
- lymfatické metastázy MeSH
- lymfatické uzliny patologie MeSH
- mikrometastázy MeSH
- nádory děložního čípku diagnóza patologie MeSH
- pánev MeSH
- senioři MeSH
- senzitivita a specificita MeSH
- spinocelulární karcinom diagnóza patologie MeSH
- staging nádorů MeSH
- tumor burden MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
OBJECTIVES: The aim of this study was to assess the detection rate, false-negative rate and sensitivity of SLN in LN staging in tumors over 2cm on a large cohort of patients. METHODS: Data from patients with stages pT1a - pT2 cervical cancer who underwent surgical treatment, including SLN biopsy followed by systematic pelvic lymphadenectomy, were retrospectively analyzed. A combined technique with blue dye and radiocolloid was modified in larger tumors to inject the tracer into the residual cervical stroma. RESULTS: The study included 350 patients with stages pT1a - pT2. Macrometastases, micrometastases, and isolated tumor cells were found in 10%, 8%, and 4% of cases. Bilateral detection rate was similar in subgroups with tumors<2cm, 2-3.9cm, and ≥4cm (79%, 83%, 76%) (P=0.460). There were only two cases with false-negative SLN ultrastaging for pelvic LN status among those with bilateral SLN detection. The false negative rate was very low in all three subgroups of different tumor sizes (0.9%, 0.9%, and 0.0%; P=0.999). Sensitivity reached 96% in the whole group and was high in all three groups (93%, 93%, 100%; P=0.510). CONCLUSIONS: If the tracer application technique is adjusted in larger tumors, SLN biopsy can be equally reliable in pelvic LN staging in tumors smaller and larger than 2cm. The bilateral detection rate and false negative rate did not differ in subgroups of patients with tumors<2cm, 2-3.9cm, and ≥4cm.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18033370
- 003
- CZ-PrNML
- 005
- 20190304105957.0
- 007
- ta
- 008
- 181008s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ygyno.2018.01.001 $2 doi
- 035 __
- $a (PubMed)29366509
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Dostálek, Lukáš, $d 1983- $7 xx0228314 $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, Czech Republic.
- 245 10
- $a SLN biopsy in cervical cancer patients with tumors larger than 2cm and 4cm / $c L. Dostálek, M. Zikan, D. Fischerova, R. Kocian, A. Germanova, F. Frühauf, L. Dusek, J. Slama, P. Dundr, K. Nemejcova, D. Cibula,
- 520 9_
- $a OBJECTIVES: The aim of this study was to assess the detection rate, false-negative rate and sensitivity of SLN in LN staging in tumors over 2cm on a large cohort of patients. METHODS: Data from patients with stages pT1a - pT2 cervical cancer who underwent surgical treatment, including SLN biopsy followed by systematic pelvic lymphadenectomy, were retrospectively analyzed. A combined technique with blue dye and radiocolloid was modified in larger tumors to inject the tracer into the residual cervical stroma. RESULTS: The study included 350 patients with stages pT1a - pT2. Macrometastases, micrometastases, and isolated tumor cells were found in 10%, 8%, and 4% of cases. Bilateral detection rate was similar in subgroups with tumors<2cm, 2-3.9cm, and ≥4cm (79%, 83%, 76%) (P=0.460). There were only two cases with false-negative SLN ultrastaging for pelvic LN status among those with bilateral SLN detection. The false negative rate was very low in all three subgroups of different tumor sizes (0.9%, 0.9%, and 0.0%; P=0.999). Sensitivity reached 96% in the whole group and was high in all three groups (93%, 93%, 100%; P=0.510). CONCLUSIONS: If the tracer application technique is adjusted in larger tumors, SLN biopsy can be equally reliable in pelvic LN staging in tumors smaller and larger than 2cm. The bilateral detection rate and false negative rate did not differ in subgroups of patients with tumors<2cm, 2-3.9cm, and ≥4cm.
- 650 _2
- $a adenokarcinom $x diagnóza $x patologie $7 D000230
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a adenoskvamózní karcinom $x diagnóza $x patologie $7 D018196
- 650 _2
- $a spinocelulární karcinom $x diagnóza $x patologie $7 D002294
- 650 _2
- $a falešně negativní reakce $7 D005188
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lymfadenektomie $7 D008197
- 650 _2
- $a lymfatické uzliny $x patologie $7 D008198
- 650 _2
- $a lymfatické metastázy $7 D008207
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mikrometastázy $7 D061206
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a pánev $7 D010388
- 650 _2
- $a senzitivita a specificita $7 D012680
- 650 _2
- $a biopsie sentinelové lymfatické uzliny $7 D021701
- 650 _2
- $a tumor burden $7 D047368
- 650 _2
- $a nádory děložního čípku $x diagnóza $x patologie $7 D002583
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Zikan, M $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, Czech Republic.
- 700 1_
- $a Fischerova, D $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, Czech Republic.
- 700 1_
- $a Kocian, R $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, Czech Republic.
- 700 1_
- $a Germanová, Anna, $d 1981- $7 xx0229091 $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, Czech Republic.
- 700 1_
- $a Frühauf, F $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, Czech Republic.
- 700 1_
- $a Dusek, L $u Institute for Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Slama, J $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, Czech Republic.
- 700 1_
- $a Dundr, P $u Department of Pathology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, Czech Republic.
- 700 1_
- $a Němejcová, Kristýna $7 xx0233214 $u Department of Pathology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, Czech Republic.
- 700 1_
- $a Cibula, D $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, Czech Republic. Electronic address: dc@davidcibula.cz.
- 773 0_
- $w MED00001958 $t Gynecologic oncology $x 1095-6859 $g Roč. 148, č. 3 (2018), s. 456-460
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29366509 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20181008 $b ABA008
- 991 __
- $a 20190304110308 $b ABA008
- 999 __
- $a ok $b bmc $g 1339441 $s 1030364
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 148 $c 3 $d 456-460 $e 20180201 $i 1095-6859 $m Gynecologic oncology $n Gynecol Oncol $x MED00001958
- GRA __
- $a NV16-31643A $p MZ0
- LZP __
- $a Pubmed-20181008